Jupiter Neurosciences Inc (JUNS) Stock AnalysisJUNSJupiter Neurosciences Inc

Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL - a proprietary, enhanced-bioavailability resveratrol formulation - is in a Phase IIa clinical trial for Parkinson's disease. The JOTROL delivery platform allows resveratrol to be consumed in an easily consumable, oral softgel in a patented micellar form. Delivered via the JOTROL platform, resveratrol infuses blood plasma and the central nervous system, and crosses the blood brain barrier, unlocking the compound's potential as a therapeutic for neurodegenerative and neurological diseases, without the GI issues. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a softgel capsule. The Company also commercializes Nugevia, a consumer longevity supplement. It also has rights in ALA-002. It operates in the Healthcare sector.

Jupiter Neurosciences, Inc. is not a good buy right now due to significant financial losses and declining stock performance. The current price is $4.18, which reflects a staggering year-to-date change of -94.48%. Additionally, the RSI is at 28.181, indicating that the stock is oversold, but this does not outweigh the risks. The company reported a net loss of $2.27 million in Q2 2026, and its gross margin is unstable, with a recent gross margin of 86.88% but significant past losses. The main risk is the high debt levels, with a debt-to-equity ratio of -17.61794, indicating financial instability.